Motolimod Combination Therapy Does Not Improve Survival in Squamous Cell Carcinoma of the Head and Neck

Share this content:
Previous studies have demonstrated that motolimod can induce positive immune responses, but it did not improve outcomes in the first-line setting in squamous cell carcinoma of the head and neck in the
Previous studies have demonstrated that motolimod can induce positive immune responses, but it did not improve outcomes in the first-line setting in squamous cell carcinoma of the head and neck in the

Motolimod plus standard chemotherapy and cetuximab (EXTREME regimen) was well tolerated, but did not lead to improvements in survival outcomes among most patients with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), according to a study published in JAMA Oncology.1

Previous studies have demonstrated that motolimod — a toll-like receptor 8 (TLR8) agonist — can induce positive immune responses, but whether it could improve outcomes in the first-line setting with the EXTREME regimen among patients with R/M SCCHN has yet to be fully investigated.

For the phase 2 Active8 (ClinicalTrials.gov Identifier: NCT01836029) study, researchers randomly assigned 195 patients to receive the EXTREME regimen (carboplatin or cisplatin, fluorouracil, cetuximab) plus placebo or motolimod every 3 weeks for 6 cycles. Patients continued to receive weekly cetuximab with either placebo or motolimod every 4 weeks thereafter.

Results showed that median progression-free survival (PFS) was 6.1 months among patients treated with motolimod compared with 5.9 months for patients who received placebo (hazard ratio [HR], 0.99;  1-sided 90% CI, 0.00-1.22; P = .47). The median overall survival (OS) was 13.5 months and 11.3 months for motolimod and placebo, respectively (HR, 0.95; 1-sided 90% CI, 0.00-1.22; P = .40).

Patients treated with motolimod had an increased incidence of injection site reactions, pyrexia, chills, anemia, and acneiform rash.

A pre-specified subgroup revealed however, that motolimod significantly prolonged survival outcomes among patients who were human papillomavirus-positive; PFS was 7.8 months compared with 5.9 months among patients treated with placebo (HR, 0.58; 1-sided 90% CI, 0.00-0.90; P = .046) and OS was 15.2 months versus 12.6 months (HR, 0.41; 1-sided 90% CI, 0.00-0.77; P = .03).

In an exploratory analysis, patients who experienced injection site reactions had improved PFS (median PFS, 7.1 vs 5.9 months; HR, 0.69; 1-sided 90% CI, 0.00-0.93; P = .06) and OS (18.7 vs 12.6; HR, 0.56; 1-sided 90% CI, 0.00-0.81; P = .02).

The authors concluded that “results provide important information regarding patient selection for treatment with TLR8 agonists and suggest that further evaluation in HPV-positive oropharyngeal cancer may be warranted.”

Reference

  1. Ferris RL, Saba NF, Gitlitz BJ, et al. Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck [published online June 21, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2018.1888

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs